External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

BACKGROUND: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, Gallego, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216357/
https://www.ncbi.nlm.nih.gov/pubmed/34211587
http://dx.doi.org/10.1177/17588359211019672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216357/
https://www.ncbi.nlm.nih.gov/pubmed/34211587
http://dx.doi.org/10.1177/17588359211019672

Ejemplares similares